Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Daiichi Sankyo Initiates Study of Two Investigational Agents for Patients with AML

americanpharmaceuticalreviewDecember 24, 2018

Tag: Daiichi Sankyo , AML , FLT3 inhibitor , MDM2 inhibitor

PharmaSources Customer Service